Parkinson's Disease Tulip


advertisement
Reply
 
Thread Tools Display Modes
Old 04-13-2017, 09:24 PM #11
Tupelo3 Tupelo3 is offline
Member
 
Join Date: Mar 2013
Location: New Jersey
Posts: 832
10 yr Member
Tupelo3 Tupelo3 is offline
Member
 
Join Date: Mar 2013
Location: New Jersey
Posts: 832
10 yr Member
Default

Quote:
Originally Posted by jeffreyn View Post
johnt said:
"A paper [1] by Sampson et al, which is behind a paywall, has some interesting findings.
...
[1] Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease, Timothy R. Sampson et al. Cell, Dec 2016."

This may turn out to be a significant paper. It was published late last year, but already has more than 30 citations. Two of these (so far) have caught my attention.

PubPeer - Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson?s Disease
Sorry I didn't notice these posts sooner. I have a copy of the Sampson et al article from Cell on "Gut Microbiota .....". I would be happy to email to anyone who is interested. Just DM your email address to me.
Tupelo3 is offline   Reply With QuoteReply With Quote

advertisement
Old 04-15-2017, 01:53 AM #12
johnt johnt is offline
Senior Member
 
Join Date: Apr 2009
Location: Stafford, UK
Posts: 1,059
15 yr Member
johnt johnt is offline
Senior Member
 
Join Date: Apr 2009
Location: Stafford, UK
Posts: 1,059
15 yr Member
Default

kiwi33 writes:

"My take on it is that we need to learn a lot more about which of the vast number of different kinds of commensual human gut bacteria are linked to health problems before we can use that knowledge to intervene clinically."

I certainly agree that there is much to learn. But, I don't think PwP have to wait until more is known before taking action. As I see it, we don't have the luxury of waiting years until everything is totally understood. That doesn't, of course, mean that we should be reckless in our investigations. We should focus on inherently safer rather than less safe therapies. We should take account of the literature, especially, where it exists, on epidemiological data. We should slowly increase the dose. We should measure the impact. We should change only one variable at a time. We should report the results, both good and bad. Etc..

jeffreyn reports of a discussion on PubPeer. I found it very interesting. Normally, when we speak of science we think of it as a "fact", but as the PubPeer discussion shows much of it is conjecture. Even when the results of research appear in a peer reviewed journal, they may prove to be incorrect.

John
__________________
Born 1955. Diagnosed PD 2005.
Meds 2010-Nov 2016: Stalevo(75 mg) x 4, ropinirole xl 16 mg, rasagiline 1 mg
Current meds: Stalevo(75 mg) x 5, ropinirole xl 8 mg, rasagiline 1 mg
johnt is offline   Reply With QuoteReply With Quote
"Thanks for this!" says:
jeffreyn (04-15-2017)
Reply

Tags
fatty, microbiota, parkinsons, patients, short

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off


Similar Threads
Thread Thread Starter Forum Replies Last Post
Can We Prevent Parkinson's Disease With N-3 Polyunsaturated Fatty Acids? Stitcher Parkinson's Disease 0 05-19-2008 03:22 PM
Omega-3 Fatty Acids Protect Against Parkinson's, Study Says Stitcher Parkinson's Disease 4 11-29-2007 01:00 PM


All times are GMT -5. The time now is 08:06 AM.

Powered by vBulletin • Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.

vBulletin Optimisation provided by vB Optimise v2.7.1 (Lite) - vBulletin Mods & Addons Copyright © 2024 DragonByte Technologies Ltd.
 

NeuroTalk Forums

Helping support those with neurological and related conditions.

 

The material on this site is for informational purposes only,
and is not a substitute for medical advice, diagnosis or treatment
provided by a qualified health care provider.


Always consult your doctor before trying anything you read here.